Skip to main content

Advertisement

Table 6 DMD choice following suboptimal response to original treatment by anti-JCV antibody status (n = 205)

From: Insights on diagnosis and therapeutic decision-making patterns for multiple sclerosis treatment: cross-sectional opinion survey results from Japanese neurologists

n (%) Preferred replacing DMD
Regardless of anti-JCV antibody status Anti-JCV antibody negative
SC IFNβ-1b IM IFNβ-1a Fingolimod Natalizumab Glatirameracetate Other SC IFNβ-1b IM IFNβ-1a Fingolimod Natalizumab Glatirameracetate Other
Current DMD SC IFNβ-1b 65 (31.7) 119 (58.1) 8 (3.9) 13 (6.3) 0 (0.0) 67 (32.7) 110 (53.7) 16 (7.8) 12 (5.9) 0 (0.0)
IM IFNβ-1a 32 (15.6) 149 (72.7) 13 (6.3) 11 (5.4) 0 (0.0) 34 (16.6) 133 (64.9) 21 (10.2) 15 (7.3) 2 (1.0)
Fingolimod 28 (13.7) 39 (19.0) 107 (52.2) 29 (14.2) 2 (1.0) 29 (14.2) 35 (17.1) 116 (56.6) 23 (11.2) 2 (1.0)
Natalizumab 20 (9.8) 18 (8.8) 90 (43.9) 59 (28.8) 18 (8.8) 18 (8.8) 17 (8.3) 105 (51.2) 52 (25.4) 13 (6.3)
Glatiramer acetate 30 (14.6) 34 (16.6) 85 (41.5) 43 (21.0) 13 (6.3) 26 (12.7) 30 (14.6) 88 (42.9) 52 (25.4) 9 (4.4)
  1. DMD disease-modifying drug, JCV John Cunningham virus, SC IFNβ-1b subcutaneous interferon beta-1b, IM IFNβ-1a intramuscular interferon beta-1a